Stuart P. Ballantine

Author

GlaxoSmithKline (United Kingdom)

Also Known As

Anthony W.J. Cooper, Stuart Ballantine, Stuart P. BALLANTINE, Stuart P. Ballantine

Publications

815

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United Kingdom)Wellcome Trust University of Dundee Age UK Molecular Discovery (United Kingdom)

About

Stuart P. Ballantine is an author at GlaxoSmithKline (United Kingdom) specializing in medicine, natural sciences, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	519
2	Natural Sciences	8	8	433
3	Biochemistry	8	8	398
4	Chemical Biology	3	3	203
5	Engineering	2	2	85

Stuart P. Ballantine

Publications

749

Citations

H-Index

Page 1

	Year	Citations
Isolation and characterisation of a soluble active fragment of hydrogenase isoenzyme 2 from the membranes of anaerobically grown Escherichia coli Stuart P. Ballantine, David H. Boxer European Journal of Biochemistry Hydrogenase Isoenzyme 2Escherichia ColiEnzymatic ModificationProtein PurificationBioenergetics	1986	134
The multifunctional folic acid synthesis <i>fas</i> gene of <i>Pneumocystis carinii</i> encodes dihydroneopterin aldolase, hydroxymethyldihydropterin pyrophosphokinase and dihydropteroate synthase Filippo Volpe, Stuart P. Ballantine, Chris J. Delves European Journal of Biochemistry EngineeringDihydroneopterin AldolaseMolecular BiologyChemical BiologyFolic Acid Synthesis	1993	75
Reassignment of the gene encoding the <i>Escherichia coli</i> hydrogenase 2 small subunit Frank Sargent, Stuart P. Ballantine, P A Rugman, European Journal of Biochemistry	1998	74
Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors J. Hamblin, Tony D. Angell, Stuart P. Ballantine, Bioorganic & Medicinal Chemistry Letters Combinatorial ChemistryNovel Structural ClassBiochemistryMedicineRational Drug Design	2008	71
Integration of Lead Optimization with Crystallography for a Membrane-Bound Ion Channel Target: Discovery of a New Class of AMPA Receptor Positive Allosteric Modulators Simon E. Ward, Mark H Harries, Laura Aldegheri, Journal of Medicinal Chemistry Proteinlipid InteractionAmpar Positive ModulatorsHigh ThroughputChemical BiologyMedicinal Chemistry	2010	65
Identification of PDE4B Over 4D subtype-selective inhibitors revealing an unprecedented binding mode Michael Kranz, Michael Wall, Brian Evans, Bioorganic & Medicinal Chemistry Molecular RecognitionMedicinal ChemistryDrug TargetNatural SciencesMedicine	2009	63
Expression of Tetanus Toxin Fragment C in E. coli: Its Purification and Potential Use as a Vaccine Andrew Makoff, Stuart P. Ballantine, Althea E. Smallwood, Nature Biotechnology Microbial ToxinE. ColiToxinologyVirulence FactorPathogenesis	1989	62
Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration Michael D. Woodrow, Stuart P. Ballantine, Michael D. Barker, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryNovel Structural ClassPharmaceutical SciencePharmaceutical Chemistry	2009	56
Discovery of<i>N</i>-[(2<i>S</i>)-5-(6-Fluoro-3-pyridinyl)-2,3-dihydro-1<i>H</i>-inden-2-yl]-2-propanesulfonamide, a Novel Clinical AMPA Receptor Positive Modulator Simon E. Ward, Mark H Harries, Laura Aldegheri, Journal of Medicinal Chemistry	2010	47
Pyrazolopyridines as potent PDE4B inhibitors: 5-Heterocycle SAR Charlotte Mitchell, Stuart P. Ballantine, Diane M. Coe, Bioorganic & Medicinal Chemistry Letters MedicineAnti-cancer AgentDrug DevelopmentPharmacologyDrug Discovery	2010	39

Page 1